PRESS RELEASES

Date	Title
Nov 16, 2022	Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
Nov 16, 2022	Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
Nov 4, 2022	National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
Nov 3, 2022	Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Nov 3, 2022	Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dial
Nov 2, 2022	Ardelyx, Inc. Reports Employment Inducement Grants
Oct 31, 2022	Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
Oct 27, 2022	Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
Oct 24, 2022	Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
Oct 20, 2022	Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022

FAQs

Email Alerts

Connect

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Milwaukee
260 East Highland Avenue
Milwaukee, WI 53202

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com